摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(4-溴苯氧)-6-甲基吡啶 | 368869-96-9

中文名称
3-(4-溴苯氧)-6-甲基吡啶
中文别名
——
英文名称
3-(4-bromophenoxy)-6-methylpyridazine
英文别名
——
3-(4-溴苯氧)-6-甲基吡啶化学式
CAS
368869-96-9
化学式
C11H9BrN2O
mdl
MFCD03086135
分子量
265.109
InChiKey
LZEJOINDIKGWQJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    142 °C
  • 沸点:
    387.6±27.0 °C(Predicted)
  • 密度:
    3 g/cm3

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    15
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.09
  • 拓扑面积:
    35
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 危险品标志:
    Xi
  • 危险类别码:
    R36/37/38

SDS

SDS:a53a82e0b29bc7662d11032bd99422cb
查看
Name: 3-(4-Bromophenoxy)-6-methylpyridazine 97% Material Safety Data Sheet
Synonym:
CAS: 368869-96-9
Section 1 - Chemical Product MSDS Name:3-(4-Bromophenoxy)-6-methylpyridazine 97% Material Safety Data Sheet
Synonym:

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS
CAS# Chemical Name content EINECS#
368869-96-9 3-(4-Bromophenoxy)-6-methylpyridazine 97% unlisted
Hazard Symbols: XI
Risk Phrases: 36/37/38

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 368869-96-9: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: brown
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 128 - 130 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H9BrN2O
Molecular Weight: 265.11

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide, hydrogen bromide, ammonia, bromine.
Hazardous Polymerization: Has not been reported

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 368869-96-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-(4-Bromophenoxy)-6-methylpyridazine - Not listed by ACGIH, IARC, or NTP.

Section 12 - ECOLOGICAL INFORMATION


Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 368869-96-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 368869-96-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 368869-96-9 is not listed on the TSCA inventory.
It is for research and development use only.


SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

  • 作为反应物:
    参考文献:
    名称:
    [EN] ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE
    [FR] ISOXAZOLINES EN TANT QU'INHIBITEURS DE L'HYDROLASE DES AMIDES D'ACIDES GRAS
    摘要:
    本发明提供了式(I)的异噁唑啉FAAH抑制剂或其药用可接受形式,其中G、Ra、Rb、Rc和Rd中的每一个如本文所定义。本发明还提供了包括式(I)化合物或其药用可接受形式以及药用可接受赋形剂的药物组合物。本发明还提供了治疗FAAH介导疾病的方法,包括向需要的受试者施用式(I)化合物或其药用可接受形式的治疗有效量。
    公开号:
    WO2010135360A1
点击查看最新优质反应信息

文献信息

  • NOVEL AZALIDE AND AZALACTAM DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE SAME
    申请人:Meiji Seika Kaisha, Ltd.
    公开号:EP1661904A1
    公开(公告)日:2006-05-31
    A compound represented by the following general formula (1) or a pharmaceutically acceptable salt thereof, which is useful for a prophylactic and/or therapeutic treatment of a microbial infectious disease. [R1 is hydrogen atom, or a linear C1-6 alkylcarbonyl group; R2 is hydrogen atom, or a C1-6 alkylcarbonyl group; R3 is hydrogen atom, a C1-6 alkyl group, a C1-6 alkylcarbonyl group, a C1-6 alkenyl group, a C2-6 alkenylcarbonyl group, a C2-6 alkynyl group, or an Ar-B- group (Ar represents an aryl group, or a heterocyclic group, and B is a C1-6 alkyl group, a C1-6 alkylcarbonyl group, a C2-6 alkenyl group, a C2-6 alkenylcarbonyl group, or a C2-6 alkynyl group); R5, R6, R7, and R8 represent hydrogen atom, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, or an Ar-B'- group (B' is a C1-6 alkyl group, a C2-6 alkenyl group, or a C2-6 alkynyl group); X is oxygen atom, or an -NR4- group (R4 is hydrogen atom, a C1-6 alkyl group, or a C1-6 alkyl group which may be substituted with an Ar group); and R4' is hydrogen atom, or a group represented by the aforementioned formula (a) (R3" and R4" represent hydrogen atom, or a linear or branched C1-6 alkylcarbonyl group)]
    由以下一般式(1)表示的化合物或其药学上可接受的盐,可用于预防和/或治疗微生物感染性疾病。[R1为氢原子,或线性C1-6烷基羰基基团;R2为氢原子,或C1-6烷基羰基基团;R3为氢原子,C1-6烷基基团,C1-6烷基羰基基团,C1-6烯基基团,C2-6烯基羰基基团,C2-6炔基基团,或Ar-B-基团(Ar表示芳基团,或杂环基团,B为C1-6烷基基团,C1-6烷基羰基基团,C2-6烯基基团,C2-6烯基羰基基团,或C2-6炔基基团);R5、R6、R7和R8表示氢原子,C1-6烷基基团,C2-6烯基基团,C2-6炔基基团,或Ar-B'-基团(B'为C1-6烷基基团,C2-6烯基基团,或C2-6炔基基团);X为氧原子,或一个-NR4-基团(R4为氢原子,C1-6烷基基团,或C1-6烷基基团,可能被芳基取代);R4'为氢原子,或由上述式(a)表示的基团(R3"和R4"表示氢原子,或线性或支链状C1-6烷基羰基基团)]
  • Nozel azalide and azalactam derivatives and method for producing the same
    申请人:Miura Tomoaki
    公开号:US20070042974A1
    公开(公告)日:2007-02-22
    A compound represented by the following general formula (1) or a pharmaceutically acceptable salt thereof, which is useful for a prophylactic and/or therapeutic treatment of a microbial infectious disease. [R 1 is hydrogen atom, or a linear C1-6 alkylcarbonyl group; R 2 is hydrogen atom, or a C1-6 alkylcarbonyl group; R 3 is hydrogen atom, a C1-6 alkyl group, a C1-6 alkylcarbonyl group, a C1-6 alkenyl group, a C2-6 alkenylcarbonyl group, a C2-6 alkynyl group, or an Ar—B— group (Ar represents an aryl group, or a heterocyclic group, and B is a C1-6 alkyl group, a C1-6 alkylcarbonyl group, a C2-6 alkenyl group, a C2-6 alkenylcarbonyl group, or a C2-6 alkynyl group); R 5 , R 6 , R 7 , and R 8 represent hydrogen atom, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, or an Ar—B′— group (B′ is a C1-6 alkyl group, a C2-6 alkenyl group, or a C2-6 alkynyl group); X is oxygen atom, or an —NR 4 — group (R 4 is hydrogen atom, a C1-6 alkyl group, or a C1-6 alkyl group which may be substituted with an Ar group); and R 4′ is hydrogen atom, or a group represented by the aforementioned formula (a) (R 3″ and R 4″ represent hydrogen atom, or a linear or branched C1-6 alkylcarbonyl group)]
    下列通式(1)所代表的化合物或其药学上可接受的盐,可用于预防和/或治疗微生物感染性疾病。[其中R1为氢原子或线性C1-6烷基羰基基团;R2为氢原子或C1-6烷基羰基基团;R3为氢原子、C1-6烷基、C1-6烷基羰基基团、C1-6烯基、C2-6烯基羰基基团、C2-6炔基或Ar-B-基团(Ar代表芳基或杂环基,B为C1-6烷基、C1-6烷基羰基基团、C2-6烯基、C2-6烯基羰基基团或C2-6炔基);R5、R6、R7和R8代表氢原子、C1-6烷基、C2-6烯基、C2-6炔基或Ar-B′-基团(B′为C1-6烷基、C2-6烯基或C2-6炔基);X为氧原子或-NR4-基团(R4为氢原子、C1-6烷基或可被芳基取代的C1-6烷基);R4′为氢原子或上述通式(a)所代表的基团(R3″和R4″代表氢原子或线性或支链状C1-6烷基羰基基团)]
  • ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE
    申请人:Behnke Mark L.
    公开号:US20110028478A1
    公开(公告)日:2011-02-03
    The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, R a , R b , R c , and R d are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient. The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.
    本发明提供了式(I)的异噁唑烷FAAH抑制剂或其药学上可接受的形式,其中G、Ra、Rb、Rc和Rd的定义如本文所述。本发明还提供了包括式(I)化合物或其药学上可接受的形式和药学上可接受的赋形剂的制药组合物。本发明还提供了治疗FAAH介导的疾病的方法,包括向需要治疗的患者施用式(I)化合物或其药学上可接受的形式的治疗有效量。
  • US7365174B2
    申请人:——
    公开号:US7365174B2
    公开(公告)日:2008-04-29
  • US9149465B2
    申请人:——
    公开号:US9149465B2
    公开(公告)日:2015-10-06
查看更多